Search

Abstract Introduction COVID‐19 drastically impacted the landscape of the United States’ medical system. Limited data is available on the nationwide implantation trends in Cardiac Resynchronization Therapy Defibrillator (CRT‐D) devices before and during the pandemic. We aimed to explore the impact of the COVID‐19 pandemic on CRT‐D insertion rates and adverse outcomes related to delays in care. Methods and Results We conducted a retrospective cross‐sectional analysis using the National Inpatient Sample database between 2017 and 2020. Variables were identified using their ICD‐10 codes. Inclusion criteria: age ≥ 18 years, presenting for a nonelective admission, primary diagnosis of hypertensive heart disease, hypertensive heart, chronic kidney disease, or heart failure, and underwent insertion of a CRT‐D. Between 2017 and 2020, CRT‐D devices were inserted during 23,635 admissions. On average, 6198 devices were implanted yearly from 2017 to 2019, with only 5040 devices being implanted in 2020. Additionally, reduced implantation rates were noted for every cohort of hospital size, location, and teaching status during this year. The year 2020 also had the highest average death rate at 1.39%, but this difference was statistically insignificant (adjusted Wald test p = .767), and COVID‐19 was not associated with an increased risk of inpatient mortality (OR 0.22, 95% CI 0.03–1.82, p = .162). Conclusion The COVID‐19 pandemic has affected all facets of the healthcare system, especially surgical volume rates. CRT‐D procedures significantly decreased in 2020. This is the first retrospective study highlighting the trend of reduced rates of CRT‐D implantation as a response to the COVID‐19 pandemic.

Abstract Novel coronavirus 2019 (COVID‐19) has been the focus of the medical community since its emergence in December 2019 and has already infected more than 100 million patients globally. Primarily described to cause a respiratory illness, COVID‐19 has been found to affect almost every organ system. Bradycardia is a newly recognized ramification of COVID‐19 that still has unknown prognostic value. Studies have shown an increase in the incidence of arrhythmias, cardiomyopathies, myocarditis, acute coronary syndromes, and coagulopathies in infected patients as well as an increased risk of mortality in patients with preexisting cardiovascular disease. While the pathogenesis of bradycardia in COVID‐19 may be multifactorial, clinicians should be aware of the mechanism by which COVID‐19 affects the cardiovascular system and the medication side effects which are used in the treatment algorithm of this deadly virus. There has yet to be a comprehensive review analyzing bradyarrhythmia and relative bradycardia in COVID‐19 infected patients. We aim to provide a literature review including the epidemiology, pathogenesis, and management of COVID‐19 induced bradyarrhythmia.